8-K: REGENXBIO and Nippon Shinyaku Partner to Advance Gene Therapies for MPS Diseases

REGENXBIO and Nippon Shinyaku have entered into an exclusive agreement to develop and commercialize RGX-121 and RGX-111 for Mucopolysaccharidosis II (MPS II) and Mucopolysaccharidosis I (MPS I), respectively.

Summary

• REGENXBIO and Nippon Shinyaku have formed a collaboration and license agreement to develop and commercialize RGX-121 for MPS II (Hunter syndrome) and RGX-111 for MPS I (Hurler syndrome).
• REGENXBIO will receive $110 million upfront and could receive up to an additional $700 million in milestone payments.
• The milestone payments consist of $40 million in potential development and regulatory milestones and $660 million in potential sales milestones.
• REGENXBIO will also receive double-digit royalties on net sales in the U.S. and certain Asian countries.
• Nippon Shinyaku will commercialize both products in the licensed territory, while REGENXBIO will lead future clinical development in the U.S.
• REGENXBIO retains all rights to the Priority Review Voucher for RGX-121.
• REGENXBIO will lead the manufacturing of both products for clinical and commercial supply in the licensed territory.
• The agreement is subject to customary closing conditions, including regulatory approvals.

Sentiment

Score: 8

Explanation: The announcement is positive due to the significant upfront payment, potential milestone payments, and royalties, as well as the partnership with a reputable company like Nippon Shinyaku. The agreement validates REGENXBIO's technology and provides additional resources to advance its pipeline.

Positives

• The partnership provides REGENXBIO with significant upfront funding and potential future revenue through milestones and royalties.
• Nippon Shinyaku's expertise in rare diseases and commercial capabilities can accelerate the development and commercialization of RGX-121 and RGX-111.
• REGENXBIO retains the rights to the Priority Review Voucher for RGX-121, which could lead to accelerated approval.
• REGENXBIO retains the right to develop and commercialize these products in countries outside of the Licensed Territory.

Negatives

• The agreement is subject to customary closing conditions, including regulatory approvals, which could delay or prevent the transaction from closing.
• The milestone payments are contingent on achieving certain development, regulatory, and sales targets, which are not guaranteed.
• The agreement contains provisions for termination under certain circumstances, such as material breach or change of control.

Risks

• The success of the collaboration depends on the ability of both companies to effectively work together and achieve their respective goals.
• Clinical trials may not be successful, and regulatory approvals may not be obtained.
• The market for gene therapies for MPS diseases may not be as large as expected.
• Competitors may develop alternative therapies that are more effective or less expensive.
• The company's reliance on a single manufacturing facility for clinical and commercial supply could create a bottleneck.

Future Outlook

REGENXBIO anticipates potential FDA approval for RGX-121 as early as late 2025 and expects the transaction with Nippon Shinyaku to close by the end of the first quarter of 2025.

Management Comments

• Curran M. Simpson, President and Chief Executive Officer, REGENXBIO, stated that the partnership maximizes collective strengths and enables access of two potentially transformational medicines to key markets.
• Toru Nakai, President and Representative Director of Nippon Shinyaku, expressed confidence that these therapies can bring tremendous value to those living with MPS II and I.

Industry Context

This agreement highlights the growing trend of partnerships between biotechnology companies to develop and commercialize gene therapies for rare diseases. It also reflects the increasing interest in the Asian market for these types of therapies.

Comparison to Industry Standards

• The upfront payment and potential milestone payments are within the typical range for licensing agreements in the gene therapy space.
• Comparable companies such as BioMarin Pharmaceutical and Sarepta Therapeutics have also entered into similar partnerships to develop and commercialize gene therapies for rare diseases.
• The double-digit royalty rates are also consistent with industry standards for this type of agreement.

Stakeholder Impact

• Shareholders will benefit from the increased financial resources and potential for future revenue.
• Patients with MPS II and MPS I may have access to new and potentially life-changing therapies.
• Employees of REGENXBIO and Nippon Shinyaku may have new opportunities for career advancement.
• The partnership could lead to increased collaboration and innovation in the gene therapy field.

Next Steps

• The transaction is expected to close by the end of the first quarter of 2025, subject to customary closing conditions.
• REGENXBIO and Nippon Shinyaku will work together to develop and commercialize RGX-121 and RGX-111.
• REGENXBIO will continue to lead clinical development in the U.S. and manufacture both products.
• Nippon Shinyaku will lead commercialization in the licensed territory.
• REGENXBIO anticipates potential FDA approval for RGX-121 as early as late 2025.

Key Dates